MEN1 and leukemia: Two molecules are currently in phase I/II clinical trials (NCT04065399, NCT04067336) for Menin–MLL inhibition (SNDX-5613 from Syndax Pharmaceuticals and KO-539 from Kura Oncology) for MLL-rearranged leukemias which show promising results.